Elicio Therapeutics (ELTX) Income from Continuing Operations (2020 - 2026)
Elicio Therapeutics' (ELTX) quarterly Income from Continuing Operations came in at 21997000.0 in Q1 2026, down 102.55% YoY from 862409458.48 in Q1 2025, and down 139.62% on a QoQ basis from 9180000.0 in Q4 2025.
Elicio Therapeutics (ELTX) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Elicio Therapeutics (ELTX) has 7 years of Income from Continuing Operations data on file, last reported at 21997000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 102.55% year-over-year to 21997000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 66186000.0 (down 25.28% YoY) and the FY2025 annual result came in at 42771000.0, up 70.52% from the prior year.
- Income from Continuing Operations fell to 21997000.0 in Q1 2026, from 9180000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 6053000.0 in Q4 2022 to a low of 21997000.0 in Q1 2026.
- A 5-year average of 12761058.82 and a median of 10860000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 83.5% in 2022, down 142.28% in 2022.
- Tracing ELTX's Income from Continuing Operations over 5 years: stood at 6053000.0 in 2022, then sank by 61.41% to 9770000.0 in 2023, then tumbled by 31.37% to 12835000.0 in 2024, then grew by 28.48% to 9180000.0 in 2025, then sank by 139.62% to 21997000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 21997000.0 (Q1 2026), 9180000.0 (Q4 2025), and 18371000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Elicio Therapeutics | 58.41 Mn | 34.91 Mn | - | -10.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -15.64 Mn |
| Mar 31, 2026 | -22.00 Mn |
| Dec 31, 2025 | -9.18 Mn |
| Sep 30, 2025 | -18.37 Mn |
| Jun 30, 2025 | -16.64 Mn |
| Mar 31, 2025 | -10.86 Mn |
| Dec 31, 2024 | -12.84 Mn |
| Sep 30, 2024 | -10.30 Mn |
| Jun 30, 2024 | -18.84 Mn |
| Mar 31, 2024 | -10.62 Mn |
| Dec 31, 2023 | -9.77 Mn |
| Sep 30, 2023 | -19.72 Mn |
| Jun 30, 2023 | -11.25 Mn |
| Mar 31, 2023 | -8.15 Mn |
| Dec 31, 2022 | -6.05 Mn |
| Sep 30, 2022 | -10.23 Mn |
| Jun 30, 2022 | -7.34 Mn |
| Mar 31, 2022 | -14.81 Mn |
| Dec 31, 2021 | 14.32 Mn |
| Sep 30, 2021 | -41.04 Mn |